Cite
HARVARD Citation
Nakayama, I. et al. (2017). Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. BMC cancer. 17 (1), pp. 1-9. [Online].